Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19551Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Nanas, J. N. | en |
| dc.contributor.author | Alexopoulos, G. | en |
| dc.contributor.author | Anastasiou-Nana, M. | en |
| dc.contributor.author | Karidis, K. | en |
| dc.contributor.author | Tirologos, A. | en |
| dc.contributor.author | Zobolos, S. | en |
| dc.contributor.author | Pirgakis, V. | en |
| dc.contributor.author | Anthopoulos, L. P. | en |
| dc.contributor.author | Sideris, D. | en |
| dc.contributor.author | Stamatelopoulos, S. F. | en |
| dc.contributor.author | Moulopoulos, S. D. | en |
| dc.date.accessioned | 2015-11-24T19:00:32Z | - |
| dc.date.available | 2015-11-24T19:00:32Z | - |
| dc.identifier.issn | 0735-1097 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19551 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adolescent | en |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Angiotensin-Converting Enzyme Inhibitors/*administration & dosage | en |
| dc.subject | Enalapril/*administration & dosage | en |
| dc.subject | Female | en |
| dc.subject | Heart Failure/*drug therapy/mortality/physiopathology | en |
| dc.subject | Hemodynamics/drug effects | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Prognosis | en |
| dc.subject | Survival Analysis | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. High Enalapril Dose Study Group | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/11127445 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0735109700010251/1-s2.0-S0735109700010251-main.pdf?_tid=dd7375ed24afc8eb9d7d0f2fc916b015&acdnat=1337847239_e93c37ac2adf291ce2940b034aecbe35 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2000 | - |
| heal.abstract | OBJECTIVES: We sought to prospectively and randomly compare survival with clinical and hemodynamic variables in patients with congestive heart failure (CHF) treated with standard versus high doses of enalapril. BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors produce hemodynamic and symptomatic benefits in patients with CHF, but there is still controversy about the optimal dose in this clinical setting. METHODS: Two hundred and forty-eight patients with advanced CHF (age 56.3+/-12 years) were randomized to receive a maximal tolerated dose of enalapril, up to 20 mg/day in group 1 (mean dose achieved 17.9+/-4.3 mg/day, n = 122) and 60 mg/day in group 2 (mean dose achieved 42+/-19.3 mg/day, n = 126). RESULTS: At enrollment, patients in group 1 were in New York Heart Association (NYHA) functional class 2.6+/-0.7 and had a mean systolic blood pressure (SBP) of 117+/-18 mm Hg, a mean heart rate (HR) of 85+/-16 beats/min and a left ventricular ejection fraction (LVEF) of 20.0+/-9.8%. In group 2, patients were in NYHA class 2.6+/-0.7; their SBP was 118+/-17 mm Hg, HR 83+/-15 beats/min and LVEF 18.8+/-8.1%. There were no significant differences in these characteristics between the two groups of patients at enrollment. After 12 months of follow-up, 22 (18%) of 122 patients in group 1 and 23 (18%) of 126 patients in group 2 had died (p = 0.995, with 80% power of the study to detect a delta difference of 13%). The NYHA class was the same (1.9+/-0.7) in both groups; SBP was 111+/-16 and 111+/-17 mm Hg, HR 77+/-12 and 79+/-13 beats/min and LVEF 31+/-19% and 30+/-12% in groups 1 and 2, respectively. These differences were not statistically significant. The study had a power of 80% to detect (p = 0.05) the following changes: 13% in death rate, 0.25 units in NYHA class, 6 mm Hg in SBP, 5 beats/min in HR and 6% in LVEF. CONCLUSIONS: No significant differences were found in survival and clinical and hemodynamic variables between patients receiving standard and those receiving high doses of enalapril. | en |
| heal.journalName | Journal of the American College of Cardiology | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Nanas-2000-Outcome of patients.pdf | 167.75 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
